RecruitingPHASE1INTERVENTIONAL

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

This study is looking at a new treatment called AZD0120 for adults living with multiple sclerosis (MS). It's quite an early stage of testing, known as 'Phase 1', which means the main goal is to check how safe the treatment is and if people can handle it without too many problems. Researchers will be carefully watching for any side effects and trying to find the best dose to use in future studies. The study involves a small number of participants, roughly 9-12 people for each type of MS being investigated. This treatment uses a clever approach involving special modified cells to target specific parts of the immune system that cause MS. The aim is to gather important information before moving on to larger studies.

At a glance

Status

Recruiting

Phase

PHASE1

Sponsor

AstraZeneca

Enrolment target

Start

09 Dec 2025

Estimated completion

07 Dec 2028

Multiple Sclerosis

What is this study about?

This study is about a new treatment, called AZD0120, for adults who have multiple sclerosis (MS). MS is a condition that affects your brain and spinal cord, which can lead to a wide range of symptoms. This new treatment, AZD0120, is a special type of cell therapy that works by targeting certain cells in your body that are thought to play a role in MS. It's a bit like giving your immune system a special instruction to help it work better and stop attacking itself.

Because this is a new treatment, the very first step in testing it is to make sure it's safe and that people can tolerate it well. This study is what's called a 'Phase 1' study, meaning that safety is the top priority. Doctors will be looking very closely for any side effects and trying to figure out the best amount of the treatment (the 'dose') to use. This information is really important because it helps scientists decide if and how to continue testing the treatment in larger groups of people.

The study is 'open-label', which means both you and your doctors will know which treatment you are receiving. It's also being carried out in several different hospitals or clinics (multi-center). By taking part, you would be helping researchers learn more about MS and potentially find new ways to treat it in the future. It's a vital step in medical research.

Key takeaways

This study is for adults with multiple sclerosis (MS).
It's testing a new treatment called AZD0120 to see if it's safe.
The study aims to find the right dose of the treatment.
It involves close monitoring by doctors and nurses.
You can withdraw from the study at any time.

Who may be eligible?

To be able to take part in this study, you need to be an adult between 18 and 60 years old. You also need to be generally well enough to participate, meaning your body needs to be functioning adequately – your doctors will check this. You'd also need to agree to take part by giving your written permission, known as 'informed consent'.

The study is looking at different types of MS. If you have what's called 'Relapsing Multiple Sclerosis' (RMS) or 'active Secondary Progressive MS' (SPMS), you might be eligible if: your symptoms have varied over time, you meet specific diagnostic criteria, you have a certain level of disability (rated on a scale where lower numbers mean less disability), and your MS has shown recent activity or you haven't responded well to other strong treatments for at least six months.

If you have 'Primary Progressive MS' (PPMS) or 'non-relapsing Secondary Progressive MS' (SPMS), you might be eligible if: your symptoms have steadily worsened, you meet specific diagnostic criteria, your disability level falls within a certain range, and you haven't responded well to at least one strong MS treatment for at least six months. There are also reasons why you might not be able to join, such as having had similar cell therapies before, certain heart conditions, or other serious brain conditions like epilepsy or a history of stroke.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you between 18 and 60 years old?
Do you have a diagnosis of Relapsing MS (RMS), active Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), or non-relapsing SPMS?
Are you generally well enough for a study, as determined by a doctor?
Have you not responded well to at least one strong MS treatment for 6 months or more, or shown recent MS activity?
Have you never had a specific type of cell therapy (CAR-T or CAR-NK) before?
Do you have any serious heart conditions or other major brain conditions like epilepsy or a history of stroke?

Answer every question to see your result.

What does participation involve?

If you join this study, you would receive the investigational treatment, AZD0120. There are two different ways (regimens) in which it might be given, and the doctors will decide which one is most suitable for you. Because this is a safety study, you can expect to have a number of visits to the clinic so that doctors and nurses can closely monitor your health. They will perform health checks, blood tests, and scans to see how you are responding to the treatment and to check for any side effects.

The exact number of visits, tests, and the total duration of your participation would be explained in detail by the study team. They will let you know how long you would need to be involved and what each visit would entail. You would be fully informed about everything before making a decision.

Potential risks and benefits

Taking part in any medical study has potential benefits and risks. A potential benefit of joining this study is that you would receive a new, experimental treatment for your MS that isn’t yet widely available. This could potentially help manage your MS if current treatments haven't been effective for you. However, as this is a very early-stage study, the main aim is to understand its safety. We don't yet know if it will definitely help your MS, and there is a possibility that it may not. There will also be potential side effects, as with any new medicine, and these will be carefully monitored. You will be given full details of these possible side effects. It's very important to remember that participating in a study is completely voluntary, and you are free to withdraw at any time without having to give a reason, and this would not affect your usual medical care.

Locations (19)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Research Site
Verified postcode
Tucson, United States· Withdrawn
Research Site
Verified postcode
Aurora, United States· Not yet recruiting
Research Site
Verified postcode
Washington D.C., United States· Not yet recruiting
Research Site
Verified postcode
St Louis, United States· Recruiting
Research Site
Verified postcode
New York, United States· Recruiting
Research Site
Verified postcode
New York, United States· Recruiting
Research Site
Verified postcode
Cleveland, United States· Not yet recruiting
Research Site
Verified postcode
Seattle, United States· Recruiting
Research Site
Verified postcode
Milwaukee, United States· Not yet recruiting
Research Site
Verified postcode
Liverpool, Australia· Not yet recruiting
Research Site
Verified postcode
Melbourne, Australia· Recruiting
Research Site
Verified postcode
Melbourne, Australia· Not yet recruiting

Common questions

What is multiple sclerosis (MS)?

MS is a condition that affects your brain and spinal cord, which are parts of your central nervous system. It can cause a wide range of symptoms like tiredness, problems with walking, and changes in vision.

What is AZD0120?

AZD0120 is a new, experimental treatment being tested for MS. It's a type of cell therapy designed to target specific cells in your body that are involved in MS.

What does 'Phase 1' study mean?

A Phase 1 study is the first step in testing a new treatment in people. The main goal is to find out if the treatment is safe and what dose can be given without causing too many problems.

Will I know if I'm getting the treatment?

Yes, this is an 'open-label' study, which means both you and your doctors will know that you are receiving the AZD0120 treatment.

Can I leave the study at any time?

Yes, taking part in a study is always voluntary. You can choose to leave the study at any point, and your decision will not affect your future medical care.

How to find out more

AstraZeneca Clinical Study Information Center

information.center@astrazeneca.com 1-877-240-9479 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.